TY - JOUR T1 - The Mexican consensus on alcoholic hepatitis JO - Revista de Gastroenterología de México T2 - AU - Velarde-Ruiz Velasco,J.A. AU - Higuera-de la Tijera,M.F. AU - Castro-Narro,G.E. AU - Zamarripa-Dorsey,F. AU - Abdo-Francis,J.M. AU - Haddad,I. Aiza AU - Aldana Ledesma,J.M. AU - Bielsa-Fernández,M.V. AU - Cerda-Reyes,E. AU - Cisneros-Garza,L.E. AU - Contreras-Omaña,R. AU - Reyes-Dorantes,A. AU - Fernández-Pérez,N.J. AU - García-Jiménez,E.S. AU - Icaza-Chávez,M.E. AU - Kershenobich-Stalnikowitz,D. AU - Lira-Pedrín,M.A. AU - Moreno-Alcántar,R. AU - Pérez-Hernández,J.L. AU - Ramos-Gómez,M.V. AU - Rizo-Robles,M.T. AU - Solana-Sentíes,S. AU - Torre-Delgadillo,A. SN - 2255534X M3 - 10.1016/j.rgmxen.2020.04.004 DO - 10.1016/j.rgmxen.2020.04.004 UR - http://revistagastroenterologiamexico.org/en-the-mexican-consensus-on-alcoholic-articulo-S2255534X20300542 AB - Alcoholic hepatitis is a frequent condition in the Mexican population. It is characterized by acute-on-chronic liver failure, important systemic inflammatory response, and multiple organ failure. The severe variant of the disease implies elevated mortality. Therefore, the Asociación Mexicana de Gastroenterología and the Asociación Mexicana de Hepatología brought together a multidisciplinary team of health professionals to formulate the first Mexican consensus on alcoholic hepatitis, carried out utilizing the Delphi method and resulting in 37 recommendations. Alcohol-related liver disease covers a broad spectrum of pathologies that includes steatosis, steatohepatitis, different grades of fibrosis, and cirrhosis and its complications. Severe alcoholic hepatitis is defined by a modified Maddrey’s discriminant function score ≥ 32 or by a Model for End-Stage Liver Disease (MELD) score equal to or above 21. There is currently no specific biomarker for its diagnosis. Leukocytosis with neutrophilia, hyperbilirubinemia (>3 mg/dl), AST > 50 U/l (< 400 U/l), and an AST/ALT ratio > 1.5-2 can guide the diagnosis. Abstinence from alcohol, together with nutritional support, is the cornerstone of treatment. Steroids are indicated for severe disease and have been effective in reducing the 28-day mortality rate. At present, liver transplantation is the only life-saving option for patients that are nonresponders to steroids. Certain drugs, such as N-acetylcysteine, granulocyte-colony stimulating factor, and metadoxine, can be adjuvant therapies with a positive impact on patient survival. ER -